Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential second-line option for patients with platinum-sensitive small cell lung cancer (SCLC) who experience relapse after treatment with platinum-based therapy.
According to Manuel Domine Gomez, MD, PhD, Jiménez Díaz Foundation University Hospital, Madrid, Spain, and coauthors, “Platinum rechallenge is generally recommended for patients with small cell lung cancer who relapse ≥90 days after completing first-line chemotherapy...however, it may not always be the most suitable or convenient option.”
Using PubMed, researchers identified and analyzed relevant articles on lurbinectedin that demonstrated the agent's mechanisms of action among patients with SCLC. Studies demonstrated that lurbinectedin is complementary to platinum-based therapy and may resensitize tumor cells due to its opposite sensitivity of SCLC cells. Efficacy analysis demonstrated that the agent is equivalent to or better than platinum rechallenge, with a more favorable hematological safety profile. Lurbinectedin is administered in 1 day compared to 3 days with platinum-based therapy. Additionally, because patients do not require granulocyte-colony stimulating factor primary prophylaxis, the degree of treatment burden is relatively better.
“Incorporation of lurbinectedin into therapeutic algorithms for relapsed SCLC has challenged long-established treatment paradigms and raised questions about treatment strategy,” concluded Dr Gomez et al. “Current evidence supports lurbinectedin as a second-line option in patients with sensitive relapsed SCLC, offering a viable alternative to platinum rechallenge.”
Source:
Gomez MD, Subbiah V, Peters S, et al. Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer. Expert Rev Anticancer Ther. Published online: December 11, 2024. doi: 10.1080/14737140.2024.2438067
